Open house Arzneimittelrabattverträge Multienzyme (Lipase, Protease etc.), ATC A09AA02
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Multienzyme (Lipase, Protease etc.), ATC A09AA02
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
No estimated contract value or volume provided; revenue is entirely dependent on actual usage and discount rate, which...
Paper submission requires two original copies and a scan sent before the 10th; electronic submission requires qualified...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Mar 2028
- Non-exclusive discount agreements for multienzyme pharmaceuticals (Lipase, Protease etc.) under ATC A09AA02
- Contracts are identical and non-negotiable for all participating pharmaceutical companies
Show full summary
Open house model for non-exclusive pharmaceutical discount agreements for multienzymes (Lipase, Protease etc., ATC A09AA02) with AOK Bayern. Any eligible pharmaceutical company can join at any time during the contract period (01.04.2026 – 31.03.2028) by submitting required documents. No estimated value provided.
Risks
No estimated contract value or volume provided; revenue is entirely dependent on actual usage and discount rate, which...
Paper submission requires two original copies and a scan sent before the 10th; electronic submission requires qualified...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company
Administrative
- Submit signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and self-declaration of reliability
- Submission in paper (two originals) or electronically with qualified electronic signature
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Multienzyme (Lipase, Protease etc.), ATC A09AA02
Non-exclusive discount agreements for multienzyme pharmaceuticals (ATC A09AA02). Contract period 01.04.2026 – 31.03.2028. Rolling entry possible by submitting documents by the 3rd of each month. No selection – all eligible companies can participate.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 15 Feb 2026
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 107164-2026
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
No estimated contract value or volume provided; revenue is entirely dependent on actual usage and discount rate, which...
Paper submission requires two original copies and a scan sent before the 10th; electronic submission requires qualified...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications